Banque Pictet & Cie SA increased its stake in shares of Eli Lilly and Co (NYSE:LLY) by 15.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 143,953 shares of the company’s stock after acquiring an additional 19,293 shares during the quarter. Banque Pictet & Cie SA’s holdings in Eli Lilly and were worth $12,314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the last quarter. BlackRock Inc. raised its stake in Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC raised its stake in Eli Lilly and by 7,093.5% during the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the last quarter. Geode Capital Management LLC raised its stake in Eli Lilly and by 8.4% during the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC raised its stake in Eli Lilly and by 2.8% during the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares during the last quarter. Hedge funds and other institutional investors own 76.31% of the company’s stock.
Eli Lilly and Co (NYSE LLY) traded up $0.59 during trading hours on Friday, hitting $86.98. The company had a trading volume of 2,730,000 shares, compared to its average volume of 3,260,000. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $95,770.00, a P/E ratio of 41.42, a P/E/G ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a 12 month low of $74.00 and a 12 month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. equities research analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is currently 99.05%.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the sale, the senior vice president now directly owns 124,522 shares in the company, valued at $10,766,172.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock worth $22,041,236 over the last quarter. 0.20% of the stock is owned by company insiders.
LLY has been the subject of several recent analyst reports. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 5th. Leerink Swann boosted their price target on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price objective (up previously from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their price objective for the company from $85.52 to $115.00 in a research report on Friday, January 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average price target of $92.14.
TRADEMARK VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/eli-lilly-and-co-lly-shares-bought-by-banque-pictet-cie-sa.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.